| Literature DB >> 11054889 |
M Edmonds1, M Bates, M Doxford, A Gough, A Foster.
Abstract
This review examines several of the recently introduced wound care products that have been put forward as treatment modalities for the diabetic foot ulcer. Discussed are the results of clinical trials with the platelet-derived growth factor, becaplermin, the tissue-engineered products Dermagraft and Apligraf, and Hyaff which is an ester of hyaluronic acid. In patients with an infected foot ulcer, encouraging results were obtained with the granulocyte-colony stimulating factor, Filgrastim. Copyright 2000 John Wiley & Sons, Ltd.Entities:
Mesh：
Substances：
Year: 2000 PMID： 11054889 DOI： 10.1002/1520-7560(200009/10)16:1+<::aid-dmrr142>3.0.co;2-s
Source DB: PubMed Journal: Diabetes Metab Res Rev ISSN： 1520-7552 Impact factor: 4.876